Binding studies of L-Prolyl-L-leucyl-glycinamide (PLG), a novel antiparkinsonian agent, in normal human brain

Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations

H. Bernheimer, W Birkmayer, Oleh Hornykiewicz et al. · Journal of the Neurological Sciences · 1973 · 2.7K citations

Life Sciences, Neurology, Neuroscience +16

"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY

C. D. Marsden, J. D. Parkes · The Lancet · 1976 · 662 citations

Medicine, Neurology, Pharmacotherapy +14

Six Years of High-Level Levodopa Therapy in Severely Akinetic Parkinsonian Patients

A. Barbeau · Archives of Neurology · 1976 · 118 citations

Medicine, Neurology, Pharmacotherapy +11

POTENTIATION OF LEVODOPA EFFECT BY INTRAVENOUS L-PROLYL-L-LEUCYL-GLYCINE AMIDE IN MAN

A. Barbeau · The Lancet · 1975 · 83 citations

Medicine, Pharmacology, Pharmacotherapy +5

Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings

Somon Chiu, C.S. Paulose, Ram K. Mishra · Peptides · 1981 · 83 citations

Medicine, Neuroscience, Pharmacology +9